Rapamycin inhibits aldolase A expression during human lymphocyte activation

Journal of Cellular Biochemistry

Volumn 63, Issue 2, 1996, Pages 239-251

  Wang, Xin ^b   Luo, Hongyu ^b   Perks, Alexandra ^b   Wu, Jiangping ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b NONE

Author keywords

cell cycle; energy metabolism; immunosuppressives; Krebs cycle; lymphocyte activation

Indexed keywords

CYCLOSPORIN A; FRUCTOSE BISPHOSPHATE ALDOLASE; RAPAMYCIN; TACROLIMUS;

ARTICLE; CELL PROLIFERATION; DRUG EFFECT; ENZYME INDUCTION; GENE EXPRESSION REGULATION; GROWTH REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

CYCLOSPORINE; FRUCTOSE-BISPHOSPHATE ALDOLASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; INTERLEUKIN-4; JURKAT CELLS; LYMPHOCYTE ACTIVATION; PHYTOHEMAGGLUTININS; POLYENES; SIROLIMUS; TACROLIMUS;

EID: 0029853867     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(19961101)63:2<239::AID-JCB11>3.0.CO;2-E     Document Type: Article

References (56)

1. Al-Bayati MA, Giri SN, Raabe OG (1990): Time and dose-response study of the effects of vanadate in rats: Changes in blood cells, serum enzymes, protein, cholesterol, glucose, calcium, and inorganic phosphate. J Environ Pathol Toxicol Oncol 10:206-213.
2. Ausubel FM, Brent R, Kinston RE, Moore DD, Seidman JG, Smith JA, Struhl K (eds) (1991): "Current Protocols in Molecular Biology." New York: John Wiley & Sons, pp 6.0.3-6.10.19.
3. Breiman A, Fawcett TW, Ghirardi ML, Mattoo AK (1992): Plant organelles contain distinct peptidylprolyl cis, transisomerases. J Biol Chem 267:4293-4296.
4. Brillantes AB, Ondrias K, Scott A, Kobrinsky E, Ondriasova E (1994): Stabilization of calcium release channel (ryanodine receptor) function by FK506 binding protein. Cell 77:513-523.
5. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL (1994): A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369:756-758.
6. Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL (1995): Control of P70 S6 kinase by kinase activity of FRAP in vivo. Nature 377:441-446.
7. Calne RY, Collier DStJ, Lim S, Pollard SG, Samaan A, White DJG, Thiru S (1989): Rapamycin for immunosuppression in organ allografting. Lancet 2:227.
8. Calvo V, Wood M, Gjertson C, Vik T, Bierer BE (1994): Activation of 70-KDa S6 kinase, induced by the cytokines interleukin-3 and erythropoietin and inhibited by rapamycin, is not an absolute requirement for cell proliferation. Eur J Immunol 24:2664-2671.
9. Cardenas ME, Heitman J (1995): FKBP12-rapamycin target TOR2 is a vacuolar protein with an associated phosphatidylinositol-4-kinase activity. EMBO J 23:5892-5907.
10. Chung J, Kuo CJ, Crabtree GR, Blenis J (1992): Rapamycin-FKBP specifically blocks growth-dependent activation of the signaling by the 70 KD S6 protein kinases. Cell 69: 1227-1236.
11. Concordet JP, Maire P, Kahn A, Daegelen D (1991): A ubiquitous enhancer shared by two promoters in the human aldolase A gene. Nucleic Acids Res. 19:4173-4180.
12. Czar MJ, Owens-Grillo JK, Yem AW, Leach KL, Deibel MR, Welsh MJ, Pratt WB (1994): The hsp56 immunophilin component of untransformed steroid receptor complexes is localized both to microtubules in the cytoplasm and to the same nonrandom regions within the nucleus as the steroid receptor. Mol Endocrinol 8:1731-1741.
13. Diamond I, Legg A, Schneider JA, Rozengurt E (1978): Glycolysis in quiescent cultures of 3T3 cells. Stimulation by serum, epidermal growth factor, and insulin in intact cells and persistence of the stimulation after cell homogenization. J Biol Chem 253:866-871.
14. Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH (1990): Distinct mechanism of suppression of murine T cell activation by the related-macrolides FK506 and rapamycin. J Immunol 144:251-258.
15. Gautron S, Maire P, Hakim V, Kahn A (1991): Regulation of the multiple promoters of the human aldolase A gene: Response of its two ubiquitous promoters to agents promoting cell proliferation. Nucleic Acids Res 19:767-774.
16. Graves LM, Bornfeldt KE, Argast GM, Krebs EG, Kong X, Lin TA, Laurence JCJr (1995): cAMP- and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells. Proc Natl Acad Sci USA 92: 7222-7226.
17. Harding MW, Galat A, Uehling DE, Schreiber SL (1989): A receptor for the immunosuppressant FK506 is a cis-trans peptidylprolyl isomerase. Nature 341:758-760.
18. Helliwell SB, Wagner P, Kunz J, Deuter-Reinhard M, Henriquez R, Hall MN (1994): TORI and TOR2 are structurally and functionally similar but not identical phosphatidylinositol kinase homologues in yeast. Mol Biol Cell 5:105-118.
19. Horecker BL, Tsolas O, Lai CY (1972): In Boyer PD (ed): "The Enzyme." New York: Academic Press, 7:213-258.
20. Imagawa M, Chiu R, Karin M (1987): Transcription factor AP-2 mediates induction by two different signal-transduction pathways: protein kinase C and cAMP. Cell 51:251-260.
21. Jin YJ, Burakoff SJ (1993): The 25-KDA FK506-binding protein is localized in the nucleus and associates with casein kinase II and nucleolin. Proc Nat Acad Sci USA 90:7769-7773.
22. Jin YJ, Albers MW, Lane WS, Bierer BE, Schreiber SL, Burakoff SJ (1991): Molecular cloning of a membrane-associated human FK506- and rapamycin-binding protein, FKBP-13. Proc Natl Acad Sci USA 88:6677-6681.
23. Job K, Arai Y, Mukai T, Hori K (1986): Expression of three mRNA species from a single rat aldolase A gene, differing in their 5′ non-coding regions. J Mol Biol 190:401-410.
24. Kishi H, Mukai T, Hirono A, Fujii H, Miwa S, Hori K (1987): Human aldolase A deficiency associated with a hemolytic anemia: Thermolabile aldolase due to a single base mutation. Proc Natl Acad Sci USA 84:8623-8627.
25. Kunz J, Henriquez R, Schneider U, Deuter-Reinhard M, Movva NR, Hall MN (1993): Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell 73:585-596.
26. Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR (1992): Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 358:70-73.
27. Lebherz HG, Rutter WJ (1969): Distribution of fructose diphosphate aldolase variants in biological systems. Biochem 8:109-121.
28. Luo H, Chen H, Daloze P, Chang J, Wu J (1992): Inhibition of in vitro immunoglobulin production by rapamycin. Transplantation 53:1071-1076.
29. Luo H, Chen H, Daloze P, St-Louis G, Wu J (1993): Anti-CD28 antibody- and IL-4-induced human T cell proliferation is sensitive to rapamycin. Clin Exp Immunol 94:371-376.
30. Luo H, Shan X, Wu J (1996): The expression of human mitochondrial NADP-dependent isocitrate dehydrogenase during lymphocyte activation. J Cell Biochem 60:495-507.
31. MacHaffie RA, Wang CH (1964): Carbonhydrate metabolism in lymphocytes. J Am Coll Health Assoc 13:126-132.
32. Maire P, Gautron S, Hakim V, Gregori C, Mennecier F, Kahn A (1987): Characterization of three optional promoters in the 5′ region of the human aldolase A gene. J Mol Biol 197:425-438.
33. Matrisian LM, Rautmann G, Magun BE, Breathnach R (1985): Epidermal growth factor or serum stimulation of rat fibroblasts induces an elevation in mRNA levels for lactate dehydrogenase and other glycolytic enzymes. Nucleic Acids Res 13:711-726.
34. Mitchell PJ, Wang C, Tjian R (1987): Positive and negative regulation of transcription in vitro: enhancer-binding protein AP-2 is inhibited by SV40 T antigen. Cell 50:847-861.
35. cdc2 kinase activation in T lymphocytes. J Biol Chem 268:22737-22745.
36. kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372:570-573.
37. + T cell dependent. J Immunol 122:2527-2533.
38. Paul WE (1991): Interleukin-4: A prototypic immunoregulatory Iymphokines. Blood 77:1859-1870.
39. Peattie DA, Harding MW, Fleming MA, Decenzo MT, Lippke JA, Livingston DJ, Benasutti M (1992): Expression and characterization of human FKBP52, an immunophilin that associates with the 90-KDA heat shock protein and is a component of steroid receptor complexes. Proc Natl Acad Sci USA 89:10974-10978.
40. Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE (1992): Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 257:973-977.
41. Roos D, Loos JA (1970): Changes in the carbohydrate metabolism of mitogenically stimulated human peripheral lymphocytes. I. Stimulation by phytohaemagglutimin. Biochim Biophys Acta 222:565-582.
42. Roos D, Loos JA (1973): Effect of phytohaemagglutinin on the carbohydrate metabolism of human blood lymphocytes after inhibition of the oxidative phosphorylation. Exp Cell Res 77:121-126.
43. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH (1994): RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78:35-43.
44. Sabatini DM, Pierchala BA, Barrow RK, Schell MJ, Snyder SH (1995): The rapamycin and FKBP12 target (RAFT) displays phosphatidyl inositol 4-kinase activity. J Biol Chem 270:20875-20878.
45. Sakakibara M, Mukai T, Hori K (1985): Nucleotidesequence of a cDNA clone for human aldolase: A messenger RNA in the liver. Biochem Biophys Res Commun 131:413-420.
46. Sehgal SN, Baker H, Vezina C (1975): Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot 28:727-732.
47. Shan X, Luo H, Chen H, Daloze P, St-Louis G, Wu J (1993): The effect of rapamycin on c-jun expression in human lymphocytes. Clin Immunol Immunopathol 69:314-317.
48. Shan X, Luo H, Houle B, Wu J (1994): Expression of a G protein β subunit-related gene during lymphocyte activation. Int Immunol 6:739-749.
49. Siekierka JJ, Hung SHY, Poe M, Lin CS, Sigal NH (1989): A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 341:755-757.
50. Steinhagen-Thiessen E, Hilz H (1979): Aldolase activity and cross-reacting material in lymphocytes of aged individuals. Gerontology 25:132-135.
51. Terada N, Patel HR, Takase K, Kohno K, Nairn AC, Gelfand EW (1994): Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. Proc Natl Acad Sci USA 91:11477-11481.
52. Terada N, Takase K, Papst P, Nairn A, Gelfand EW (1995): Rapamycin inhibits ribosomal protein synthesis and induces G1 prolongation in mitogen-activated T lymphocytes. J Immunol 155:3418-3426.
53. Tocci MJ, Matkovich DA, Collier KA, Kwok P, Dumont F, Lin S, Degudicibus S, Siekierka JJ, Chin J, Hutchinson NI (1989): The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 143:718-726.
54. Vezina C, Kudelski A, Sehgal SN (1975): Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antiobiot 28:721-726.
55. Wang T, Foker JE, Tsai MY (1980): The shift of an increase in phosphofructokinase activity from protein synthesis-dependent to -independent mode during concanavalin A induced lymphocyte proliferation. Biochem Biophys Res Commun 95:13-19.
56. Yeh WC, Bierer BE, McKnight SL (1995): Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells. Proc Natl Acad Sci USA 92:11086-11090.